Background-Angiotensin
H ypertension and heart failure (HF) are major causes of death and morbidity in the Western world, and their prevalence is projected to increase. [1] [2] [3] Increasing recognition that sustained overdrive of neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS) is involved in HF pathophysiology has led to the introduction of drugs inhibiting key components of the RAAS into clinical practice. [4] [5] [6] The success of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARB) underscores the importance of RAAS as a target in these (and other) cardiovascular disorders.
Clinical Perspective on p 78
In addition to the RAAS, counter-regulatory hormonal pathways are also activated in HF. The natriuretic peptide (NP) system counteracts the RAAS by promoting vasodilation, natriuresis, and inhibition of fibrosis and hypertrophy. 7, 8 Biologically active NPs are degraded by the enzyme neutral endopeptidase or neprilysin; consequently, neprilysin inhibition represents an important pharmacological approach to augment the salutary actions of NPs. Presumably because of its affinity toward multiple substrate peptides beyond the NPs such as endothelin-1 and angiotensin II, stand-alone neprilysin inhibitor (NEPi) has not been proven to be clinically efficacious. 9, 10 Simultaneous blockade of RAAS and neprilysin through dual-acting ACE and NEPi (vasopeptidase inhibitors) has been evaluated a decade ago. Its prototypic drug, omapatrilat, showed favorable effects in clinical trials of hypertension and HF, but further development was halted because of increased rates of angioedema, presumably caused by accumulation of bradykinin in at-risk patients. 11, 12 Recently, a new drug class, angiotensin receptor neprilysin inhibitors (ARNi), have been developed to simultaneously block the RAAS and augment NPs through neprilysin inhibition at a presumed lower risk of bradykinin-induced angioedema. 13, 14 In a preclinical model, ARNi (using valsartan-candoxatril) provided similar antihypertensive efficacy as omapatrilat without inducing tracheal plasma extravasation (a surrogate of angioedema). 15 LCZ696 has been the first ARNi to be evaluated in patients with hypertension and HF. [16] [17] [18] LCZ696 combines a moiety of the ARB valsartan and the NEPi precursor, AHU377. After intake, LCZ696 is metabolized into active valsartan and inactive AHU377, whereas AHU377 is further cleaved into the active NEPi LBQ657. LCZ696 thus far has shown promising efficacy without significant occurrence of off-target effects. However, the effects of ARNi (LCZ696) on cardiac fibrosis, hypertrophy, and remodeling after myocardial infarction (MI) remain to be established.
We therefore hypothesized that LCZ696 would have beneficial effects on cardiac remodeling after experimental MI, and that this may be contributed to by inhibition of hypertrophy and fibrosis in cardiac cells.
Methods

Induction of MI, Treatment, and Study Protocol
Adult 6-to 8-week-old male Sprague-Dawley rats (220-250 g body weight) were subjected to induction of MI by left anterior descending ligation as routinely performed in our laboratory. 19 Rats were randomized in a 2:1 fashion to 4 weeks of treatment with LCZ696 (68 mg/kg body weight perorally; MI-ARNi, n=11) or vehicle (MI-Vhc, n=6). LCZ696 was a kind gift of Novartis, Basel, Switzerland. Treatment commenced 1 week after surgery (baseline) to avoid interference with reparative scar formation. Glomerular filtration rate (GFR), proteinuria, serum, and urinary creatinine were determined and echocardiography performed before treatment was commenced. Five weeks after MI (end point), systolic blood pressure was measured in conscious rats using the tail-cuff method before being placed in a metabolic cage for a 24-hour period with free access to food and water. GFR and renal functional parameters were then measured, and animals were allowed to rest. On the following day, cardiac function was assessed by echocardiography and invasive left ventricular (LV) catheterization, respectively, before rats were euthanized and organs harvested.
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Echocardiography and Hemodynamic Measurements
Standard 2-dimensional and Doppler echocardiography was performed before and after 4 weeks of treatment in lightly anesthetized animals (40 mg/kg ketamine and 5 mg/kg IP xylazine) using a commercially available system (GE Vingmed Vivid 7, Horten, Norway) with a 10-MHz phased array probe, as routinely used in our laboratory. 19 All recordings were analyzed off-line by an experienced specialist using commercially available customized software within a personal computer workstation (EchoPac vers108.1.0, GE Vingmed, Horten, Norway). LV basal rotation and systolic circular LV strain were determined by speckle tracking analysis of LV basal short axis views. 20 Diastolic wall strain, an index of diastolic stiffness based on the linear elastic theory, was defined as the difference between systolic and diastolic posterior wall thickness divided by systolic posterior wall thickness. 21 Animals were anesthetized with pentobarbitone (60 mg/kg IP) and intubated for cardiac catheterization procedures, as previously described. 19 Briefly, animals were ventilated and a 2-F miniaturized combined catheter/ micromanometer (model SPR838; Millar Instruments, Houston, TX) was inserted into the right common carotid artery to obtain aortic blood pressure and then advanced into the left ventricle to obtain LV pressurevolume loops. Pressure-volume loops were recorded at steady state and during transient preload reduction, achieved by occlusion of the inferior vena cava and portal vein with the ventilator turned off and animal apnoeic. The following validated parameters were assessed using Millar conductance data acquisition and analysis software PVAN 3.5: LV end-systolic pressure, LV end-diastolic pressure, maximal and minimal change in pressure over time (dP/dt max and dP/dt min ), τ (t Logistic), and the slope of the preload recruitable stroke work relationship. At the conclusion of the measurements, tissues were harvested and fixed in neutral buffered formalin and processed for histopathology.
The investigation conformed with the Guide for the Care 
Histological Analysis of Cardiac Tissue
Paraffin-embedded LV tissue sections (4 μm) were stained with picrosirius red to determine interstitial fibrosis using Aperio ScanScope Console v.8.0.0.1058 (AperioTechnologies, Inc). Picrosirius red staining in the noninfarct zone and peri-infarct zone of the LV was selected for its intensity of staining, and the percentage area was calculated using an established algorithm. 19 Similarly, perivascular fibrosis was defined as the area of picrosirius red staining immediately surrounding the adventitita of the intramural coronary arteries. The intensity and algorithm were preset and maintained constant for analysis of all sections. Infarct size was expressed as an averaged percentage of the endocardial and epicardial scarred circumferences of the LV.
Cellular Cardiac Hypertrophy and Fibrosis In Vitro
Rat neonatal cardiac myocytes and fibroblasts were obtained from 1-to 2-day-old Sprague-Dawley rat pups by enzymatic collagenase digestion and prepared for in vitro assays as routinely used in our laboratory. 22 Cardiac myocyte hypertrophy was assessed by AngII-stimulated (100 nmol/L) neonatal cardiac myocytes with 3[H]leucine incorporation for 60 hours. AngII-stimulated (100 nmol/L) collagen synthesis was determined by 3 [H]proline incorporation in neonatal cardiac fibroblasts for 48 hours. Cells were preincubated with valsartan, AHU377, LBQ657, or valsartan+LBQ657 (ARNi) for 1 hour before stimulation. Dose ranges used and NEPi to ARB ratios aimed to replicate as far as possible doses of LCZ696 used clinically. The drugs were a kind gift of Novartis, Basel, Switzerland. In addition, exogenous B-type natriuretic peptide (BNP) was added at different concentrations into the cell culture media just before AngII stimulation to assess the effect of direct augmentation of NP signaling. Experiments were repeated 2 to 4× in triplicate each time.
Statistical Analysis
Values are expressed as mean±SEM. For in vivo experiments, unpaired Student t test was used. For cell studies, 1-way ANOVA with Bonferroni post hoc analysis was used for comparison among all groups and paired t test was used for comparisons between treated groups using GraphPad Prism software version 5 as described.
22 A 2-tailed P value of <0.05 was considered significant.
Results
Effects of ARNi on Cardiac Hypertrophy and Fibrosis After Experimental MI
After 4 weeks of treatment, MI-ARNi exhibited significantly smaller weights compared with MI-Vhc in all cardiac chambers, consistent with reduced cardiac hypertrophy ( Table 1) . Lung and kidney weights were similar between groups. Although heart rate was comparable, blood pressure trended to be lower with LCZ696 versus MI-Vhc. The degree of fibrosis both in noninfarcted remote myocardium ( Figure 1A ) and in the periinfarct zone ( Figure 1B ) was significantly reduced in MI-ARNi versus MI-Vhc. In contrast, no differences in perivascular fibrosis in noninfarcted ( Figure 1C ) or peri-infarct ( Figure 1D ) myocardium were discerned.
Effects of ARNi on LV Remodeling and Function
Infarct size was substantial and consistent with large MI, and similar in both groups ( Figure 1E ). Echocardiography 1 week after MI before treatment demonstrated similar LV dimensions and function in both groups ( Table 2) .
At end point, MI-ARNi exhibited smaller LV cavity dimensions with unaltered wall thickness versus MI-Vhc (Table 3) . Computed LV mass with MI-ARNi was lower than MI-Vhc, consistent with organ weights. Ejection fraction and fractional area change were increased, as was diastolic wall strain.
Doppler echocardiography analysis revealed similar early and reduced late diastolic filling and a trend toward higher E/A ratios in MI-ARNi versus MI-Vhc. This was reflected by a similar pattern of early and late myocardial velocities by TDI. E/é ratios (an estimate of LV filling pressure) and systolic myocardial velocities were similar between groups. At similar degree of basal rotation, circular strain was increased in MI-ARNi versus MI-Vhc.
Hemodynamics in ARNI-Versus Vehicle-Treated Rats After MI
Analysis of steady-state LV pressure-volume loops in vivo revealed no statistically significant differences in heart rate, LV volumes, LV pressures, cardiac output, or arterial pressures (Table 1) . However, LV unloading by caval vein occlusion revealed a significantly higher end-systolic pressure-volume relationship (P<0.001), lower τ (P<0.05), and a trend for lower end-diastolic pressure-volume relationship (P=0.10) in MI-ARNi versus MI-Vhc animals.
Renal Function After MI
Renal function in MI-Vhc and MI-ARNi at baseline was similar, and neither urinary creatinine nor proteinuria changed significantly in either group. Despite small increases in plasma creatinine in both groups during the study period, the difference between values at end point versus baseline was significant only in MI-Vhc (not shown). GFR significantly decreased in both groups and to a greater extent in MI-Vhc; accordingly, both absolute GFR values at end point (MI-Vhc 7.1±0.5 versus MI-ARNi 8.3±0.3 mL/min per kilogram; P=0.07) and the difference in changes in GFR over time (MI-Vhc −4.7±0.7 versus MI-ARNi −3.6±0.2 mL/min per kilogram; P=0.09) nearly reached significance.
Effects of Stand-Alone NEPi on Cellular Cardiac Fibrosis and Hypertrophy
AngII induced profound collagen accumulation in fibroblasts ( Figure 2A ) and cardiac myocyte hypertrophy ( Figure 2B) , respectively, as has been shown previously. 22 The inactive NEPi precursor, AHU377, did not inhibit collagen accumulation in fibroblasts nor cardiac myocyte hypertrophy (data not shown). In cardiac fibroblasts, the active NEPi LBQ657 had no discernible effects (Figure 2A ). In contrast, LBQ657 modestly inhibited cardiac myocyte hypertrophy ( Figure 2B ).
Effects of Stand-Alone ARB and ARNi on Cardiac Fibrosis and Hypertrophy
Valsartan dose dependently inhibited collagen accumulation in fibroblasts ( Figure 3A ) and cardiac myocyte hypertrophy ( Figure 3B ), respectively. In cardiac fibroblasts, addition of LBQ657 (10 μmol/L) significantly augmented the inhibitory effects of valsartan except for the highest dose where both valsartan and valsartan+LBQ657 values were reduced to unstimulated negative control values ( Figure 4A ). In cardiac myocytes, addition of LBQ657 (10 μmol/L) significantly augmented the inhibitory effects of the lowest dose of valsartan; however, only the highest combined dose of ARNi (valsartan+LBQ657) afforded complete inhibition of AngII-induced hypertrophy to values that were similar to unstimulated negative controls ( Figure 4B ).
BNP Reduced AngII-Stimulated Cellular Cardiac Hypertrophy and Cardiac Fibrosis
Increasing doses of BNP into culture media dose dependently reduced AngII-stimulated collagen synthesis in cardiac fibroblasts ( Figure 5A ) as well as cardiac myocyte hypertrophy ( Figure 5B ). The highest BNP dose (ie, 10 −8 mol/L) resulted in inhibition at levels that were not different from unstimulated negative controls.
Discussion
We herein present novel data on the effects of LCZ696, a firstin-class ARNi, on post-MI cardiac remodeling and on AngIIinduced hypertrophy and fibrosis in cardiac cell lines.
First, our data show that treatment with LCZ696 versus vehicle resulted in attenuation of cardiac dysfunction, fibrosis and remodeling, and somewhat attenuated decline in kidney function in rats after experimental MI. Second, although the inactive NEPi precursor, AHU377, did not affect AngII-stimulated cellular cardiac hypertrophy and fibrosis, its active metabolite LBQ657 in vitro modestly inhibited cardiac hypertrophy, but not cardiac fibrosis. Third, valsartan potently inhibited AngIIstimulated cellular cardiac hypertrophy and cardiac fibrosis. Fourth, concomitant LBQ657 and valsartan augmented the effects of the stand-alone ARB valsartan in cell culture. Finally, BNP dose dependently inhibited AngII-mediated effects in both cell types, providing further rationale for augmentation of salutary NP effects in cardiac hypertrophy and fibrosis.
Cardiac dysfunction and remodeling were attenuated by 4 weeks treatment with LCZ696, commencing 1 week after experimental MI. The delay in commencement of treatment aimed to avoid interference with reparative scar tissue formation and hemodynamic stabilization. Despite large and similar infarct size in both groups, organ weights and cardiac dimensions (by echocardiography) consistently showed a 15% to 20% reduction in LV size by LCZ696. Moreover, echocardiography and in vivo hemodynamic measurements revealed better preservation of cardiac function. Although early diastolic LV inflow and myocardial velocities were not different, lower late diastolic LV inflow, reduced diastolic wall strain (ie, an index of LV diastolic stiffness), lower τ, higher end-diastolic pressure-volume relationship, and reduced atrial size all support better-preserved diastolic function. This is consistent with effects of LCZ696 to reduce atrial adverse remodeling in patients with heart failure with preserved ejection fraction even in the absence of discernible effects on LV diastolic filling. 17 Here, MI rats did not exhibit signs of overt HF, for example, elevated lung weights but it may be reasonable to assume that HF would have developed during longer observation time, although the study was not designed to assess evolution to HF or mortality. The observed improvements in cardiac function afforded by LCZ696 may be related both to reduced cardiac hypertrophy (as manifest by decreased LV weight and mass) and a reduction in interstitial fibrosis in the peri-infarct and remote myocardium, but not perivascular fibrosis. Further mechanistic studies are required to elucidate the precise effect on profibrotic signaling cascades.
A previous report investigating dual pathway inhibition with omapatrilat versus the ARB candesartan demonstrated that both agents attenuated LV remodeling and dysfunction as well as several profibrotic peptides in rats after ischemia-reperfusion injury. 23 In addition, Bäcklund et al 24 showed superior efficacy of omapatrilat versus captopril on cardiomyocyte apoptosis and cardiac remodeling after MI. LCZ696 also seems to show similar increased efficacy beyond stand-alone RAAS blockade as omapatrilat in this study. The clinical introduction of omapatrilat had been halted because of increased rates of angioedema in clinical trials leading to the development of ARNi. Our in vitro studies were designed to test whether effects of LCZ696 on LV remodeling were contributed to by direct actions on relevant cardiac cell types. Furthermore, we were specifically interested in whether NEPi resulted in incremental effects on cardiac fibrosis as well as hypertrophy, in addition to that achieved by ARB. Our data did not demonstrate an in vitro effect of the inactive NEPi prodrug AHU377 in either cell type. This is consistent with the established mode of action of AHU377 requiring enzymatic cleavage to LBQ657, the active inhibitor of neprilysin. LBQ657, however, showed a distinct pattern of action in the different cell types. In cardiac fibroblasts, no discernible effect of LBQ657 at any tested dose was found despite clear add-on effects (when added to valsartan) and despite similar efficacy of exogenous BNP to inhibit AngII-mediated signaling in that cell type. Although not specifically tested, increase in other, potentially unfavorable neprilysin substrates such as endothelin or even AngII itself may have counteracted NEPi-induced augmentation of BNP, resulting in neutral effects on collagen accumulation. This is consistent with neutral net effects of NEPi in humans. 9, 10, 25 In contrast, stand-alone LBQ657 was found to attenuate hypertrophy in cardiac myocytes.
Predictably, valsartan potently attenuated AngII-induced signaling in both cell types. Addition of LBQ657 to valsartan (replicating an ARNi) further augmented inhibitory effects. This was also observed in cardiac fibroblasts in which standalone LBQ657 did not produce discernible effects despite cardiac fibroblasts having been shown to produce BNP in response to various noxious stimuli. 26 In contrast, in cardiac myocytes, the net effect of stand-alone neprilysin inhibition (by LBQ657) was of attenuation of hypertrophy. Both in cardiac fibroblasts and in myocytes only the highest ARNi dose afforded complete inhibition of AngII-mediated signaling. In line with important effects of NP augmentation by LBQ657, BNP potently inhibited AngII-induced signaling in both cardiac cell lines.
In patients with HF, elevated NP levels are frequently found in concert with the degree of cardiac dysfunction and symptom status. Despite their natriuretic and diuretic effects, administration of synthetic NPs has failed to improve clinical outcomes, at least in the acute setting. Conceptually ARNi offers the advantage of augmenting endogenous NPs, combining their benefits with those of ARBs, well-established drugs in hypertension and HF. Contemporary clinical data underscore the efficacy of ARNi in patients with hypertension and heart failure with preserved ejection fraction to alter blood pressure and important surrogate end points, with an acceptable safety profile. 16, 17, 27 Recently, the prospective comparison of ARNi with angiotensin-converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF), a large (n=8422) outcome study assessing efficacy and safety of LCZ696 versus the angiotensin-converting enzyme inhibitors, enalapril, in patients with HF and reduced ejection fraction was stopped prematurely after interim analysis suggested superiority over standard therapy with angiotensin-converting enzyme inhibitors, the current gold standard.
18,28 PARADIGM-HF will likely provide definite answers on the efficacy and safety of LCZ696 in HF. Given that many patients in PARADIGM-HF have an ischemic basis to their LV dysfunction, the findings of the present study will likely provide mechanistic insight into the benefits of LCZ696 in PARADIGM. 29 
Limitations
This study used only male rats, thus sex differences in efficacy, if any, cannot be determined from this work. The PARADIGM-HF trial did not show heterogeneity in efficacy response across sexes.
The use of sedation and anesthesia for echocardiography and invasive hemodynamic assessment, respectively, may have influenced the results. However, we used a consistent level of anesthesia across all animals reflected by similar Effects of single angiotensin receptor blocker, valsartan on cellular cardiac fibrosis and hypertrophy. As expected, angiotensin (Ang) II-stimulated collagen synthesis in cardiac fibroblasts (A) and cardiac myocyte hypertrophy (B), respectively, were robustly and dose dependently inhibited by angiotensin receptor blockade with valsartan. Yet, the degree of inhibition did not increase much further from the second highest to highest valsartan concentration consistent with leveling off of valsartan efficacy at either cell type. Even at the highest valsartan concentration a small but significant residual AngII-stimulated effect still could be observed. ****P<0.0001, AngII vs control; ###P<0.001, ####P<0.0001, valsartan vs AngII.
heart rates so any effects should be like-for-like across both study groups.
In summary, we have shown that the ARNi LCZ696 attenuated cardiac remodeling and dysfunction after experimental MI and inhibited cardiac fibrosis and cardiac hypertrophy in vivo after MI, as well as in vitro beyond that achieved by stand-alone ARB. Our data may offer novel mechanistic insight into the benefits observed with LCZ696 in clinical studies. The present findings suggest that LCZ696, by combining RAAS blockade with augmentation of beneficial NP effects, has potential as a novel therapeutic agent after MI as well as in a broader spectrum of cardiovascular disorders. 
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